Avidity Biosciences Inc (NASDAQ:RNA) has a beta value of 0.78 and has seen 1.06 million shares traded in the last trading session. The company, currently valued at $1.92B, closed the last trade at $24.13 per share which meant it lost -$0.57 on the day or -2.31% during that session. The RNA stock price is -14.63% off its 52-week high price of $27.66 and 80.02% above the 52-week low of $4.82. The 3-month trading volume is 1.14 million shares.
Avidity Biosciences Inc (NASDAQ:RNA) trade information
Sporting -2.31% in the red in last session, the stock has traded in the red over the last five days, when the RNA stock price touched $24.13 or saw a rise of 6.55%. Year-to-date, Avidity Biosciences Inc shares have moved 166.63%, while the 5-day performance has seen it change -4.02%. Over the past 30 days, the shares of Avidity Biosciences Inc (NASDAQ:RNA) have changed -8.60%.
Avidity Biosciences Inc (RNA) estimates and forecasts
Figures show that Avidity Biosciences Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 395.48% over the past 6 months, with this year growth rate of -5.50%, compared to 12.60% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are -5.40% and -18.20% for the next quarter. Revenue growth from the last financial year stood is estimated to be 7.10%.
7 analysts offering their estimates for the company have set an average revenue estimate of $2.93 million for the current quarter. 7 have an estimated revenue figure of $2.81 million for the next quarter concluding in Jun 2024. Year-ago sales stood $2.23 million and $2.14 million respectively for this quarter and the next, and analysts expect sales will grow by 31.20% for the current quarter and 31.30% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -57.60% over the past 5 years.
RNA Dividends
Avidity Biosciences Inc is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
